Bristol-Myers Squibb to Acquire Amylin Pharmaceuticals for $5.3 Billion

Bristol-Myers Squibb (BMS; New York) and biopharmaceutical company Amylin Pharmaceuticals (San Diego, CA) say that BMS will acquire Amylin for $31/share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of about $5.3 billion. Amylin is focused on the discovery, development and commercialization of medicines for patients with diabetes and other metabolic diseases. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly, together totaling about $1.7...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers